Leap Therapeutics’ New Data from the Company’s Phase 2a DisTinGuish study will be presented at the ASCO Symposium in January 2022. Dr. Samuel Klempner, Chief Medical Officer and Chairman of the Board of Directors of the Company, will discuss the study results on a conference call on January 21, 2022. Part A of the DisGuish study will be presented, which includes first-line treatment of advanced G/GEJ patients with high tumoral DKK1 expression. The fresh data shows that the combination of paclitaxel and high tumoral DKK1 expression is associated with improved clinical responses and survival. Also, data from the ongoing Part B study will be presented, which shows that the treatment was well tolerated.
The mixture of tislelizumab and DKN-01 has been shown to improve overall survival in patients with advanced gastroesophageal junction cancer whose tumors express high levels of DKK1. “These data continue to support the potential of DKN-01 to improve the survival rate of patients with this challenging setting.” Dr. Klempner added that the data supporting the use of DKN-01 in combination with tislelizumab in the first-line treatment of patients with this challenging setting should be presented in a randomized clinical trial.